Related Experiment Video
Updated: Apr 26, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.6K
Mycophenolate in refractory and relapsing lupus nephritis
Francisco Rivera1, Evangelina Mérida, Maria L Illescas
1Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
American Journal of Nephrology
|August 7, 2014
Summary
Mycophenolate (MF) effectively treats lupus nephritis (LN). Switching to MF from other treatments is safe and shows high response rates in refractory and relapsing lupus nephritis patients.
Area of Science:
- Nephrology
- Immunosuppression
- Autoimmune Diseases
Background:
- Mycophenolate (MF) is an established treatment for lupus nephritis (LN).
- This study focuses on MF's efficacy and safety in refractory and relapsing LN cases.
Purpose of the Study:
- To evaluate the effectiveness of Mycophenolate (MF) in patients with refractory and relapsing lupus nephritis (LN).
- To assess the safety profile of MF in this patient cohort.
Main Methods:
- Retrospective analysis of 85 patients with refractory (35) and relapsing (50) LN from 11 Spanish nephrology departments.
- Primary endpoints: renal response and relapse rates. Secondary endpoint: side effects.
- Patients switched to MF from other immunosuppressants, primarily cyclophosphamide.
Main Results:
- 87% of patients achieved a renal response (69% partial, 31% complete).
- No significant association found between baseline clinical/analytical data and response rates.
- Low relapse rate (15.7%) after MF discontinuation, with no clinical predictors identified. Side effects were generally mild, with one fatality due to thrombocytopenia.
Conclusions:
- Switching to Mycophenolate (MF) is an effective strategy for managing refractory and relapsing lupus nephritis (LN).
- MF demonstrates a favorable safety profile in this patient population.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
01:28Pulmonary Tuberculosis V
974
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
974
01:26Nephrotic Syndrome II : Assessment and Medical Management
406
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
406
01:24Nephrotic Syndrome I : Introduction
1.1K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K
01:26Psychosis: Goals of Pharmacotherapy
695
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
695